Literature DB >> 6197100

Cerebrospinal fluid probenecid studies: a reinterpretation.

R W Cowdry, M H Ebert, D P van Kammen, R M Post, F K Goodwin.   

Abstract

Probenecid is used to block the transport of acid monoamine metabolites from cerebrospinal fluid (CSF), on the assumption that the resultant rise in CSF concentrations of the metabolites will reflect presynaptic "turnover" of the parent monoamine. However, CSF levels of probenecid correlate with CSF levels of the metabolite, suggesting that the blockade is incomplete at the probenecid levels obtained in human studies. This article reviews the literature on CSF probenecid-metabolite correlations and presents data demonstrating variations in the correlations across diagnostic groups. These cross-diagnostic variations may be due to group differences in membrane transport characteristics and and confound attempts to "correct for" CSF probenecid concentrations in studies of monoamine turnover.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6197100

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  3 in total

1.  Determinations of 5-hydroxyindoleacetic acid and homovanillic acid in human CSF with monitoring of probenecid levels in CSF and plasma.

Authors:  B M Emanuelsson; E Widerlöv; H Walléus; L K Paalzow
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Liquid chromatographic assay for cerebrospinal fluid serotonin.

Authors:  M Linnoila; K A Jacobson; T H Marshall; T L Miller; K L Kirk
Journal:  Life Sci       Date:  1986-02-24       Impact factor: 5.037

3.  Acute Pannexin 1 Blockade Mitigates Early Synaptic Plasticity Defects in a Mouse Model of Alzheimer's Disease.

Authors:  Carolina Flores-Muñoz; Bárbara Gómez; Elena Mery; Paula Mujica; Ivana Gajardo; Claudio Córdova; Daniela Lopez-Espíndola; Claudia Durán-Aniotz; Claudio Hetz; Pablo Muñoz; Arlek M Gonzalez-Jamett; Álvaro O Ardiles
Journal:  Front Cell Neurosci       Date:  2020-03-19       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.